Welcome to the December 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we explore a few key abstracts in the MPN landscape that were presented at the recent 2018 American Society of Hematology Annual Meeting. We also spotlight other MPN research, including the frequency of pulmonary hypertension among this patient population and survival outcomes based on age.
Additionally this month, we explore review articles on new guidelines for the management of complications associated with polycythemia vera, as well as how dose escalation of ruxolitinib impacts the risk of grade 3/4 adverse events.
If you haven’t yet, check out our helpful MPN management resources, including an expert roundtable panel discussion, “Management of Myeloproliferative Neoplasms: A Case-Based Discussion;” my interview with a patient who has been managing her MPN diagnosis for the past 15 years; and our “Fast Facts” guides with MPN incidence and mortality data and diagnostic criteria.
As always, I hope you find this newsletter and its contents to be a useful and enduring resource in your practice. Please feel free to share it with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Lindsey Lyle, MS, PA-C
Senior Instructor, Blood Cancers and Bone Marrow Transplant Program
University of Colorado, Anschutz Medical Campus